Hotpennystocknews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angeles, CA -- (SBWIRE) -- 02/06/2014 -- Hotpennystocknews.com issues special report on - Affymetrix (AFFX)
Affymetrix, Inc.(AFFX), is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level.
In 2014, Affymetrix expects to generate revenues of $335 million, which is higher than the current Zacks Consensus Estimate of $330 million. The company also expects EBITDA margin in the range of 12 to 13%.
In January, Affymetrix received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its CytoScan Dx Assay. The CytoScan assay is intended for the postnatal detection of DNA copy number variants in patients who required chromosomal testing. It is designed to help physicians diagnose children's developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations.
AFFX posted adjusted earnings of $2.2 million or 2 cents per share in the fourth quarter of 2013 in stark contrast to a loss of $1.3 million or 2 cents a share in the same quarter of 2012. However, earnings failed to meet the Zacks Consensus Estimate of 7 cents per share.
Reported earnings were $9.4 million or 10 cents per share in the quarter compared with a loss of $12.3 million or 17 cents per share in the fourth quarter of 2012. The turnaround result was caused by increase in revenues and decrease in costs and expenses during the quarter.
Revenues increased 9.8% to $92.6 million, beating the Zacks Consensus Estimate of $86 million. Product revenues improved 7.5% to $82.1 million, while Service and other revenues surged 32.1% to $10.5 million in the reported quarter.
Product revenues included consumable sales of $57.6 million, up 8.5%, and instrument revenues of $4.0 million, down 23.1% from the prior-year quarter. Revenues from the acquired eBioscience unit increased 13.3% to $20.5 million in the quarter. Service and other revenues include field and scientific services revenues of $4.6 million and royalties and other of $600,000.
For earnings history and earnings-related data on Affymetrix, Inc.(AFFX)
Neither Hotpennystocknews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by Hotpennystocknews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.Hotpennystocknews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through Hotpennystocknews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in.
Read Full disclaimer at:http://www.hotpennystocknews.com/disclaimer.php
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)